July 12, 2018 09:42 AM EDT
R&D

On the heels of GW's epilep­sy win, Wall Street dar­ling Zo­genix shares pos­i­tive PhI­II da­ta on ri­val drug

Brittany Meiling

A ri­val is al­ready loom­ing for GW Phar­ma­ceu­ti­cals $GW­PH, the drug­mak­er who scored the very first cannabis-de­rived drug ap­proval on­ly weeks ago to treat rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times